Replies to post #91 on Ardelyx Inc (ARDX)

[Whalatane]

Am. pill burden is huge for those taking phosphate binders . The risk most see with ARDX is increased diarrhea ...but according to my wife ..a PA at a dialysis clinic ...most of her patients complain of constipation so a little looser stool may bring them back to what they remember as " normal "

I need to catch up on ARDX ...results soon.? I have positions in RETA and CCXI ( plus others ) so have been busy lately
Kiwi

[Whalatane]

This is what we are waiting for ...from recent CC

The company currently expects to announce results in the fourth quarter of 2019 from the PHREEDOM clinical trial, the company's second Phase 3 clinical trial evaluating tenapanor as a monotherapy treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis.


Kiwi